AREG mediates transient hepatocellular carcinoma resistance to receptor tyrosine kinase inhibitors
Cell Reports · 2026-11 · 45 (11) · 118196
DOI: 10.1016/j.celrep.2026.118196 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2026-11. Verfasst von Limu Lou und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Science and Technology, ShanghaiTech University, Shanghai 200032, China; Shanghai Clinical Research and Trial Center, Shanghai 201210,…. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Lenvatinib is a first-line therapy for hepatocellular carcinoma (HCC), yet resistance remains a major clinical challenge. Emerging studies suggest resistance evolves through dynamic multi-step processes. Here, using multi-timepoint and multi-omics sampling, we characterized the trajectory of lenvatinib resistance in HCC cells and identified three adaptive states marked by state transitions. Multi-omics analyses and functional validation identified amphiregulin (AREG) as a key transient mediator of resistance in our models. AREG is a sufficient and dominant ligand to promote cell survival through epidermal growth factor receptor (EGFR) activation. Pharmacological inhibition of the AREG-EGFR axis specifically targeted early-resistant cells. Furthermore, AREG upregulation was validated in additional replicate experiments and another HCC cell line. Mechanistically, a focal deletion on chromosome 3p may contribute to NF-κB activation and AREG expression. This study delineates a recurrent yet transient adaptive mechanism and suggests new therapeutic opportunities-such as combination therapies targeting transient resistance mechanisms-to prevent or overcome drug resistance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Life Science and Technology, ShanghaiTech University, Shanghai 200032, China; Shanghai Clinical Research and Trial Center, Shanghai 201210, China.
- Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai 200032, China.
- Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai 200032, China. Electronic address: yunfan_…
- School of Life Science and Technology, ShanghaiTech University, Shanghai 200032, China; Shanghai Clinical Research and Trial Center, Shanghai 201210, China. Electronic address: zhangly@shanghaitech.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Lou, L., Feng, H., Zhang, X., Wang, H., Fan, Y., Tao, Y., Zhang, Z., Lin, C. P., Sun, Y., & Zhang, L. (2026). AREG mediates transient hepatocellular carcinoma resistance to receptor tyrosine kinase inhibitors. Cell Reports, 45(11), 118196. https://doi.org/10.1016/j.celrep.2026.118196
Vancouver
Lou L, Feng H, Zhang X, Wang H, Fan Y, Tao Y, et al. AREG mediates transient hepatocellular carcinoma resistance to receptor tyrosine kinase inhibitors. Cell Reports. 2026;45(11):118196. doi:10.1016/j.celrep.2026.118196
BibTeX
@article{Lou2026,
author = {Lou, Limu and Feng, Haokang and Zhang, Xinxin and Wang, Heng and Fan, Yunhao and Tao, Yibao and Zhang, Zefan and Lin, Chao-Po and Sun, Yunfan and Zhang, Liye},
title = {AREG mediates transient hepatocellular carcinoma resistance to receptor tyrosine kinase inhibitors},
journal = {Cell Reports},
year = {2026},
volume = {45},
number = {11},
pages = {118196},
doi = {10.1016/j.celrep.2026.118196}
}
EUVIMED